Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06 |
|
Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06 ±³À°ÁÖÁ¦ : 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ ´ã´çÀÚ : ±èÇýÁø À̸ÞÀÏ : hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú Âü¼®¿¹»óÀοø : 200¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 80,000¿ø ºñ°í Àü°øÀÇ,°£È£»ç,±âŸ 50000¿ø
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:15~09:35 Current status of hemophilia care in China Renchi Yang(Institute of Haematology and Blood Diseases Hospital, China) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:35~09:55 Current Situation and Issues in Hemophilia in Japan Michio Sakai(Munakata Suikokai General Hospital, Japan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:55~10:15 Current Situation and Issues in Hemophilia in Korea Ki-Young Yoo(Korea Hemophilia Foundation, Korea) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:15~10:35 Current Situation and Issues in Hemophilia in Taiwan Chia-Yao Chang(Taipei Medical University Hospital, Taiwan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:35~10:55 Current therapeutic landscape and future directions in the management of haemophilia in Australia Huyen Tran(Australia Haemophilia Centre Directors) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 11:20~12:00 Advances in hemophilia A treatment after emicizumab Midori Shima(Thrombosis and Hemostasis Research Center, Japan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 12:10~12:50 Optimizing the benefits of personalized prophylaxis based on the real world experience Robert Klamroth(Vivantes Klinikum Friedrichshain, Germany) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:00~13:20 Emicizumab for Individual Needs of Japanese People Living with Hemophilia: Impacts and Unsolved Issues Ei Kinai(Tokyo Medical University, Japan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:20~13:40 The role of low-dose prophylaxis and low-dose ITI for hemophilia children in developing countries. Runhui Wu(Beijing Children¡¯s Hospital, China) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:40~14:00 Individualized Treatment Using Population Pharmacokinetics for Patients with Hemophilia in Taiwan Yeu-Chin Chen(Tri-Service General Hospital, Taiwan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:00~14:20 Current treatment pattern in hemophilia, based upon data the HIRA(health insurance review agency) and KBDR (Korean bleeding disorder registry) Jung Woo Han(Yonsei University Health System, Korea) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:45~15:05 Hemophilia patients with Inhibitors in China Wei Liu(Blood Diseases Hospital (Institute of Hematology), China) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:05~15:25 The frontiers of diagnosis and treatment in Japanese hemophilia patients with inhibitors based on prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2) Koji Yada(National Hospital Organization Osaka National Hospital, Japan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:25~15:45 Current status in hemophilia patients with inhibitors in Korea YoungShil Park(Kyung Hee University Hospital, Korea) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:45~16:05 Efficacy, safety, and cost of emicizumab prophylaxis in hemophilia A patients with inhibitor: a nationwide observation study in Taiwan Jiaan-Der Wang(Taichung Veterans General Hospital, Taiwan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:30~16:50 Clinical hemostasis prediction through current monitoring technology in bleeding disorders Naruto Shimonishi(Nara Medical University, Japan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:50~17:10 The application of NGS for the diagnosis of hereditary platelet disorders Donglei Zhang(Zhongnan Hospital of Wuhan University, China) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:10~17:30 Laboratory monitor of factor VIII: perceive in the era of emicizumab Te-Fu Weng(Chung Shan Medical University Hospital, Taiwan) ±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:30~17:50 Application of primary data of coagulometer assays Jae Woo Song(Yonsei University Health System, Korea)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|